Vincent Meiffrédy

1.0k citations

24 papers · 767 indexed · h-index 14

Co-authors: J Aboulker Philippe Flandre Patrick Yéni Françoise Brun‐Vézinet Jean‐François Delfraissy Gilles Pialoux François Raffi Véronique Joly
Topics: HIV Research and Treatment (19 papers)HIV/AIDS drug development and treatment (15 papers)HIV/AIDS Research and Interventions (12 papers)
Cited by: Virology Infectious Diseases Emergency Medicine
Journals: New England Journal of Medicine The Lancet PLoS ONE
Partner nations: France Martinique Australia

In The Last Decade

Vincent Meiffrédy

24 papers receiving 741 citations

Peers

Countries citing papers authored by Vincent Meiffrédy

Since Specialization

Citations

This map shows the geographic impact of Vincent Meiffrédy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent Meiffrédy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent Meiffrédy more than expected).

Fields of papers citing papers by Vincent Meiffrédy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent Meiffrédy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent Meiffrédy. The network helps show where Vincent Meiffrédy may publish in the future.

Co-authorship network of co-authors of Vincent Meiffrédy

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent Meiffrédy. A scholar is included among the top collaborators of Vincent Meiffrédy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent Meiffrédy. Vincent Meiffrédy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The build-up of stock of stable integrated proviruses overtime explains the difficulty in reducing HIV-1 DNA levels when treatment is initiated at the chronic stage of the infection 2023 ·Journal of Virus Eradication ·(unknown),Antoine Chéret,Adeline Mélard,Asma Essat,(unknown),Rebecca Bauer,Caroline Charre,Vincent Meiffrédy,Lionel Piroth,Cécile Goujard,Laurence Meyer,Véronique Avettand-Fènoël	3
2	Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial 2022 ·Journal of Antimicrobial Chemotherapy ·Antoine Chéret,Rebecca Bauer,Vincent Meiffrédy,(unknown),Faïza Ajana,Karine Lacombe,Philippe Morlat,C. Lascoux,Jacques Reynes,Ruxandra Câlin,Sylvie Abel,Cécile Goujard,Christine Rouzioux,Véronique Avettand-Fènoël,Laurence Meyer	7
3	Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients 2018 ·AIDS ·Nathalie Verdière,Christine Durier,Assia Samri,Vincent Meiffrédy,Odile Launay,Sophie Matheron,Séverine Mercier‐Delarue,(unknown),J Aboulker,Jean‐Michel Molina,Brigitte Autran,François Simon	18
4	Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype 2017 ·PLoS ONE ·Séverine Mercier‐Delarue,Christine Durier,Nathalie Verdière,Jean‐Dominique Poveda,Vincent Meiffrédy,María Dolores Fernández-García,Stéphane Lastère,Raymond Césaire,(unknown),Jean‐Michel Molina,Ali Amara,François Simon	14
5	Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial 2012 ·Vaccine ·Nicole Le Corre,(unknown),Claire Pouteil Noble,Vincent Meiffrédy,(unknown),R. Cahen,Isabelle Charreau,(unknown),(unknown),J Aboulker,Brigitte Autran,Emmanuel Morélon,Benoı̂t Barrou	24
6	Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial) 2011 ·HIV Medicine ·Eoin R. Feeney,Corine Chazallon,Niall O’Brien,Vincent Meiffrédy,Ruth Goodall,(unknown),(unknown),P. Yéni,Patrick Mallon	4
7	Incidence and Risk Factors of Thrombocytopenia in Patients Receiving Intermittent Antiretroviral Therapy: A Substudy of the ANRS 106-Window Trial 2009 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Marie‐Anne Bouldouyre,Isabelle Charreau,B. Marchou,(unknown),Christine Katlama,Philippe Morlat,Vincent Meiffrédy,Daniel Vittecoq,Philippe Bierling,J Aboulker,Jean‐Michel Molina	11
8	Interruption of Antiretroviral Therapy Initiated during Primary HIV-1 Infection: Impact of a Therapeutic Vaccination Strategy Combined with Interleukin (IL)-2 Compared with IL-2 Alone in the ANRS 095 Randomized Study 2007 ·AIDS Research and Human Retroviruses ·Cécile Goujard,Fabienne Marcellin,Houria Hendel‐Chavez,Marianne Burgard,Vincent Meiffrédy,Alain Venet,Christine Rouzioux,(unknown),Raphaëlle El Habib,Maria Beumont‐Mauviel,J Aboulker,Yves Lévy,Jean‐François Delfraissy,(unknown)	39
9	Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals 2006 ·AIDS ·Yves Lévy,Christine Durier,Anne‐Sophie Lascaux,Vincent Meiffrédy,Hanne Gahéry‐Ségard,Cécile Goujard,Christine Rouzioux,(unknown),Jean‐Gérard Guillet,Michel D. Kazatchkine,Jean‐François Delfraissy,J Aboulker	65
10	Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults 2006 ·AIDS ·Christine Durier,Odile Launay,Vincent Meiffrédy,Yacine Saïdi,Dominique Salmon,Yves Lévy,Jean‐Gérard Guillet,Gilles Pialoux,J Aboulker	49
11	Experience using MedDRA for global events coding in HIV clinical trials 2005 ·Contemporary Clinical Trials ·(unknown),Yacine Saïdi,Vincent Meiffrédy,(unknown),(unknown),(unknown),J Dormont,(unknown)	13
12	Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073) 2004 ·Journal of Clinical Virology ·Diane Descamps,Véronique Joly,Philippe Flandre,Gilles Peytavin,Vincent Meiffrédy,Séverine Mercier‐Delarue,Stéphane Lastère,J Aboulker,Patrick Yéni,Françoise Brun‐Vézinet	4
13	Final analysis of the Trilège induction-maintenance trial: results at 18 months 2002 ·AIDS ·Philippe Flandre,François Raffi,Diane Descamps,Vincent Cálvez,(unknown),Vincent Meiffrédy,(unknown),(unknown),Gilles Pialoux,J Aboulker,F. B. Vezinet	16
14	Effect of Zidovudine Resistance Mutations on Virologic Response to Treatment With Zidovudine or Stavudine, Each in Combination With Lamivudine and Indinavir 2002 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Diane Descamps,Philippe Flandre,Véronique Joly,Vincent Meiffrédy,Gilles Peytavin,Jacques Izopet,Catherine Tamalet,(unknown),(unknown),Stéphane Lastère,J Aboulker,Patrick Yéni,Françoise Brun‐Vézinet	9
15	Increased risk of lipoatrophy under stavudine in HIV-1-infected patients 2002 ·AIDS ·Véronique Joly,Philippe Flandre,Vincent Meiffrédy,Nicolas Leturque,(unknown),J Aboulker,Patrick Yéni	142
16	Efficacy of Zidovudine Compared to Stavudine, Both in Combination with Lamivudine and Indinavir, in Human Immunodeficiency Virus-Infected Nucleoside-Experienced Patients with No Prior Exposure to Lamivudine, Stavudine, or Protease Inhibitors (Novavir Trial) 2002 ·Antimicrobial Agents and Chemotherapy ·Véronique Joly,Philippe Flandre,Vincent Meiffrédy,Françoise Brun‐Vézinet,Jean‐Albert Gastaut,Cécile Goujard,Gérard Rémy,Diane Descamps,Annick Ruffault,Agnès Certain,J Aboulker,(unknown)	20
17	Adherence to Antiretroviral Therapy and Outcomes in HIV-Infected Patients Enrolled in An Induction/Maintenance Randomized Trial 2002 ·Antiviral Therapy ·Philippe Flandre,Gilles Peytavin,Vincent Meiffrédy,Yacine Saïdi,Diane Descamps,(unknown),Françoise Brun‐Vézinet,François Raffi,(unknown)	27
18	Adverse Reactions to Cotrimoxazole in HIV-infected Patients: Predictive Factors and Subsequent HIV Disease Progression 2001 ·Scandinavian Journal of Infectious Diseases ·(unknown),Isabelle Charreau,(unknown),François Raffi,Vincent Meiffrédy,(unknown),Françis Guillemin,Patrick Yéni,(unknown)	19
19	CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART 2001 ·Clinical & Experimental Immunology ·Daniel Scott‐Algara,J.-P. Aboulker,Christine Durier,Edgar Badell,Fabienne Marcellin,(unknown),C Jouanne,Vincent Meiffrédy,Françoise Brun‐Vézinet,Gilles Pialoux,François Raffi	12
20	A Randomized Trial of Three Maintenance Regimens Given after Three Months of Induction Therapy with Zidovudine, Lamivudine, and Indinavir in Previously Untreated HIV-1–Infected Patients 1998 ·New England Journal of Medicine ·Gilles Pialoux,François Raffi,Françoise Brun‐Vézinet,Vincent Meiffrédy,Philippe Flandre,Jean‐Albert Gastaut,P. Dellamonica,Patrick Yéni,Jean‐François Delfraissy,J Aboulker	174

About Vincent Meiffrédy

Vincent Meiffrédy is a scholar working on Virology, Infectious Diseases and Hepatology, having authored 24 papers that have together received 767 indexed citations. Recurring topics across this work include HIV Research and Treatment (19 papers), HIV/AIDS drug development and treatment (15 papers) and HIV/AIDS Research and Interventions (12 papers). The work is most often cited by research in Virology (526 citations), Infectious Diseases (561 citations) and Emergency Medicine (221 citations). Vincent Meiffrédy has collaborated with scholars based in France, Martinique and Australia. Frequent co-authors include J Aboulker, Philippe Flandre, Patrick Yéni, Françoise Brun‐Vézinet, Jean‐François Delfraissy, Gilles Pialoux, François Raffi, Véronique Joly, Nicolas Leturque and Jean‐Albert Gastaut. Their work appears in journals such as New England Journal of Medicine, The Lancet and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact